Chemistry:Ropsacitinib
From HandWiki
Ropsacitinib (PF-06826647) is a drug which is an orally active, selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various autoimmune inflammatory conditions, primarily plaque psoriasis.[1][2][3]
See also
- Brepocitinib
- Deucravacitinib
References
- ↑ "Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors". Dermatology and Therapy 13 (2): 417–435. February 2023. doi:10.1007/s13555-022-00878-9. PMID 36592300.
- ↑ "Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors". Journal of Medicinal Chemistry 66 (7): 4378–4416. April 2023. doi:10.1021/acs.jmedchem.2c01800. PMID 36951608.
- ↑ "TYK2: an emerging therapeutic target in rheumatic disease". Nature Reviews. Rheumatology 20 (4): 232–240. April 2024. doi:10.1038/s41584-024-01093-w. PMID 38467779.
 |  |
